Assembly Biosciences (ASMB)

• Market cap: $430M
• 1 day: -0.38%
• 5 days: 1.83%
• 1 month: -17.02%
• 3 months: -20.25%
• 6 months: -21.67%
• Year to date: -37.45%
• 1 year: -25.7%
• 5 years: -45.54%
• 10 years: -86.68%
• Sector: Healthcare
• Industry: Biotechnology

About: Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.

Employees: 73